HK19595A - Fluoxetine useful for the treatment of diabetes - Google Patents

Fluoxetine useful for the treatment of diabetes

Info

Publication number
HK19595A
HK19595A HK19595A HK19595A HK19595A HK 19595 A HK19595 A HK 19595A HK 19595 A HK19595 A HK 19595A HK 19595 A HK19595 A HK 19595A HK 19595 A HK19595 A HK 19595A
Authority
HK
Hong Kong
Prior art keywords
fluoxetine
diabetes
useful
treatment
mammals
Prior art date
Application number
HK19595A
Other languages
English (en)
Inventor
David Taiwai Wong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK19595A publication Critical patent/HK19595A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
HK19595A 1987-05-04 1995-02-09 Fluoxetine useful for the treatment of diabetes HK19595A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4550987A 1987-05-04 1987-05-04

Publications (1)

Publication Number Publication Date
HK19595A true HK19595A (en) 1995-02-17

Family

ID=21938301

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19595A HK19595A (en) 1987-05-04 1995-02-09 Fluoxetine useful for the treatment of diabetes

Country Status (11)

Country Link
EP (1) EP0294028B1 (xx)
JP (1) JP2721507B2 (xx)
KR (1) KR880013555A (xx)
AT (1) ATE93721T1 (xx)
AU (1) AU596296B2 (xx)
DE (1) DE3883606T2 (xx)
DK (1) DK238588A (xx)
ES (1) ES2058272T3 (xx)
HK (1) HK19595A (xx)
PH (1) PH23901A (xx)
ZA (1) ZA883115B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2039103A1 (en) * 1990-03-29 1991-09-30 David Wayne Robertson Improvements in and relating to the selective occupation of serotonin 1c receptors
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
US20150190352A1 (en) 2012-07-31 2015-07-09 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine in animals
EA201590047A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина для увеличения мясной и молочной продуктивности
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
ZA861211B (en) * 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition

Also Published As

Publication number Publication date
EP0294028A2 (en) 1988-12-07
AU1553388A (en) 1988-11-10
ZA883115B (en) 1990-01-31
ES2058272T3 (es) 1994-11-01
KR880013555A (ko) 1988-12-21
DK238588A (da) 1988-11-05
JPS63284126A (ja) 1988-11-21
EP0294028A3 (en) 1990-05-02
AU596296B2 (en) 1990-04-26
EP0294028B1 (en) 1993-09-01
ATE93721T1 (de) 1993-09-15
DE3883606T2 (de) 1994-01-20
DE3883606D1 (de) 1993-10-07
DK238588D0 (da) 1988-05-03
JP2721507B2 (ja) 1998-03-04
PH23901A (en) 1989-12-18

Similar Documents

Publication Publication Date Title
AU581269B2 (en) Difluoronucleosides
EP0189680A3 (en) Stabilizing power source apparatus
JPS5791915A (en) Novel lipid composition useful for dietetics, resuscitation and treatment
GB2081695B (en) Surface treatment for carbon
EP0294028A3 (en) Fluoxetine useful for the treatment of diabetes
EP0311061A3 (en) Composition for the surface treatment of rubber
NO881270D0 (no) Framgangsmaate for aa redusere carboninnholdet i halvledere.
IE882529L (en) Platinum Coordination Compound
GB2211845B (en) Process for dechlorinating 4,5-dichlorofluoro-dioxolanes to obtain fluorodioxoles
EP0310893A3 (en) Vulcanizable fluororubber composition
IL85189A0 (en) Alkylmelatonins
GR79753B (xx)
GB2198451B (en) Briquette treatment process
EP0238765A3 (en) 2,2-diphenoxy-n,n-dimethylaminoethane for improving cerebral oxygenation
GB2206821B (en) Improvements relating to surface treatment
ZA884799B (en) Novel treatment
GB8708576D0 (en) Distillation process
ZA884770B (en) Process for the oxidation of coal
GB8702771D0 (en) Treatment for burn
YU149786A (en) Process for alkylizing izoparaffin with olephinic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)